Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03576508 · ClinicalTrials.gov registry record · Phase 1

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

A Phase 1 study of Knee Osteoarthritis, sponsored by Centrexion Therapeutics.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT03576508 is a Phase 1 study of Knee Osteoarthritis that has completed, run by Centrexion Therapeutics. The registered enrollment target is 16 participants, below the 304-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03576508, a Phase 1 study of Knee Osteoarthritis, has completed, sponsored by Centrexion Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1b, open-label, two-period, randomized crossover study in adult male and female participants with painful knee osteoarthritis.

Conditions Studied

Interventions

  • DRUG CNTX-4975-05
  • DRUG Qutenza
  • DRUG Lidocaine (without epinephrine)

Study Locations (1)

Florida

  • Well Pharma Medical Research, Corp - Miami

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2018-06-25
Est. Completion 2018-09-06
Phase Phase 1

Sponsor

Centrexion Therapeutics

12 total trials

What the Registry Record Tells You About NCT03576508

The ClinicalTrials.gov registry entry for NCT03576508 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 304-participant average among 101 other Knee Osteoarthritis trials with a reported enrollment target (95% lower). The listed sponsor is Centrexion Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Knee Osteoarthritis appearing as the primary indexed condition, and to 3 interventions - of which CNTX-4975-05 is the first listed.

NCT03576508 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03576508 about?

NCT03576508 is a clinical study titled "A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis". This is a Phase 1b, open-label, two-period, randomized crossover study in adult male and female participants with painful knee osteoarthritis.

What is the current status of trial NCT03576508?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-06-25. Estimated completion is 2018-09-06.

What conditions does trial NCT03576508 study?

This clinical trial studies the following conditions: Knee Osteoarthritis.

What interventions are being tested in trial NCT03576508?

The interventions under investigation include: CNTX-4975-05 (DRUG), Qutenza (DRUG), Lidocaine (without epinephrine) (DRUG).

Who is sponsoring clinical trial NCT03576508?

This trial is sponsored by Centrexion Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03576508 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Knee Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.